Incyte

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Incyte and other ETFs, options, and stocks.

About INCY

Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. It focuses on hematology and oncology, and inflammation and autoimmunity therapeutic areas.

CEO

William J. Meury

CEOWilliam J. Meury

Employees

2,844

Employees2,844

Headquarters

Wilmington, Delaware

HeadquartersWilmington, Delaware

Founded

1991

Founded1991

Employees

2,844

Employees2,844

INCY Key Statistics

Market cap

19.97B

Market cap19.97B

Price-Earnings ratio

15.80

Price-Earnings ratio15.80

Dividend yield

—

Dividend yield—

Average volume

2.11M

Average volume2.11M

High today

$103.16

High today$103.16

Low today

$100.05

Low today$100.05

Open price

$101.32

Open price$101.32

Volume

805.29K

Volume805.29K

52 Week high

$112.29

52 Week high$112.29

52 Week low

$53.56

52 Week low$53.56

Stock Snapshot

As of today, Incyte(INCY) shares are valued at $100.35. The company's market cap stands at 19.97B, with a P/E ratio of 15.80.

On 2026-02-23, Incyte(INCY) stock moved within a range of $100.05 to $103.16. With shares now at $100.35, the stock is trading +0.3% above its intraday low and -2.7% below the session's peak.

Trading volume for Incyte(INCY) stock has reached 805.29K, versus its average volume of 2.11M.

Over the past 52 weeks, Incyte(INCY) stock has traded between a high of $112.29 and a low of $53.56.

INCY News

Simply Wall St 17h

Incyte Expands Latin Reach As NIKTIMVO Push Meets Mixed Valuation Signals

Incyte (NasdaqGS: INCY) has expanded its partnership with Knight Therapeutics in Latin America, adding exclusive distribution rights for key therapies. The com...

TipRanks 5d

Knight Therapeutics announces NIKTIMVO regulatory submission in Brazil

Knight Therapeutics (KHTRF) announced that its Brazilian affiliate, United Medical, has submitted a marketing authorization application to ANVISA, the Brazilian...

Simply Wall St 5d

Assessing Incyte Valuation After Earnings Beat And Positive 2026 Revenue Outlook

Incyte (INCY) is back in focus after reporting fourth quarter and full year 2025 results that topped revenue expectations and issuing 2026 net product revenue g...

Analyst ratings

48%

of 27 ratings

Buy

40.7%

Hold

48.1%

Sell

11.1%

More INCY News

TipRanks 5d

Incyte price target raised to $117 from $116 at Barclays

Barclays raised the firm’s price target on Incyte (INCY) to $117 from $116 and keeps an Overweight rating on the shares. Published first on TheFly – the ultima...

People also own

Based on the portfolios of people who own INCY. This list is generated using Robinhood data, and it’s not a recommendation.

Credo Technology Group

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.